AlzeCure Pharma
AlzeCure Pharma publishes prospectus
THIS PRESS RELEASE MAY NOT BE PUBLISHED, PUBLISHED OR DISTRIBUTED, DIRECTLY OR INDIRECTLY IN OR TO RUSSIA, BELARUS, AUSTRALIA, HONG KONG, JAPAN, CANADA, NEW ZEALAND, SWITZERLAND, SINGAPORE, SOUTH AFRICA, UNITED STATES OF AMERICA OR ANY OTHER JURISDICTION WHERE SUCH ACTION IS IN WHOLE OR IN PART FOR LEGAL RESTRICTIONS. THIS PRESS RELEASE DOES NOT CONSTITUTE AN OFFER TO ACQUIRE SECURITIES IN ALZECURE PHARMA AB. SEE ALSO THE “IMPORTANT INFORMATION” SECTION BELOW.
The prospectus regarding AlzeCure Pharma AB's ("AlzeCure" or "Company") rights issue with preferential rights for the Company's shareholders of approximately SEK 53 million, decided by the board on March 26, 2024 and subsequently approved by an extraordinary general meeting on April 25, 2024, has been approved and registered by the Swedish Financial Supervisory Authority (“Finansinspektionen”).
The prospectus is available on the Company's website, www.alzecurepharma.com, on Zonda Partners' website, www.zondapartners.com, and Nordic Issuing's website, www.nordic-issuing.se. The prospectus will also be made available on the Financial Supervisory Authority's website, www.fi.se.
Important information
The information in this press release neither contains nor constitutes an offer to acquire, subscribe or otherwise trade in shares, warrants or other securities in AlzeCure. No action has been taken and no action will be taken to permit an offer to the public in any jurisdictions other than Sweden. The invitation to interested persons to subscribe for shares in AlzeCure will only take place through the prospectus that AlzeCure expects to be able to publish on April 29, 2024.
The information in this press release may not be disclosed, published or distributed, directly or indirectly, within or to the United States, Belarus, Russia, Australia, Hong Kong, Japan, Canada, New Zealand, Switzerland, Singapore, South Africa or any other jurisdiction where such action would be illegal, subject to legal restrictions or require measures other than those that follow from Swedish law. Actions contrary to this instruction may constitute a violation of applicable securities legislation. No shares or other securities of AlzeCure have been registered, and no shares or other securities will be registered, under the United States Securities Act of 1933 from time to time ("Securities Act") or the securities laws of any state or other jurisdiction of the United States and may not be offered, sold or otherwise transferred, directly or indirectly, in or to the United States, except pursuant to an applicable exemption from, or in a transaction not subject to, the registration requirements of the Securities Act and pursuant to the securities laws of the relevant state; or other jurisdiction in the United States. This communication is distributed and directed only to persons in the United Kingdom who are (i) professional investors falling within the scope of Article 19(5) of the U.K. from time to time. Financial Services and Markets Act 2000 (Financial Promotion) Order 2005 ("the Order") or (ii) high net worth subjects and other persons to whom this notice may lawfully be addressed, who are subject to Article 49(2)(a)-(d) ) in the Order (all such persons are collectively referred to as "Relevant Persons"). Persons who are not Relevant Persons may not act on or rely on the information in this communication. An investment or investment measure referred to in this communication is only possible for Relevant Persons and will only be completed with Relevant Persons. Persons who disseminate this communication must themselves ensure that such dissemination is permitted.
Datum | 2024-04-29, kl 14:30 |
Källa | MFN |
![](https://static.allaaktier.se/ads/hand-waving-2.png)